重度抑郁症药物治疗相关的磁共振研究进展

Research advances of magnetic resonance imaging related to drug therapy of major depressive disorder

重度抑郁症(MDD)是一种高度异质性的精神疾病,抗抑郁药是MDD治疗的首选方案,其中选择性5-羟色胺再摄取抑制剂(SSRI)及5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRI)是临床中常用的抗抑郁药物。但是目前临床用药主要依赖医生的临床经验,疗效的个体差异性较大,缺乏客观的疗效评估指标。本文对SSRI和SNRI治疗中不同抗抑郁药物疗效相关的磁共振神经影像特征进行综述,旨在寻找可预测或评估SSRI、SNRI类抗抑郁药疗效共有的和特异的神经影像学特征,为MDD患者的个体化精准治疗、提高治疗效果提供参照。

Major depressive disorder(MDD)is a highly heterogeneous disease.Antidepressants are the preferred treatment for MDD,among which selective serotonin reuptake inhibitors(SSRI)and serotonin and norepinephrine reuptake inhibitors(SNRI)are commonly used antidepressants in clinical practice.However,currently clinical medication treatment mainly relies on the clinical experience of doctors,with significant individual differences in efficacy and a lack of objective efficacy evaluation indicators.This article reviews the magnetic resonance neuroimaging features related to the efficacy of SSRI and SNRI,aiming to find the common or specific neuroimaging features that can predict or evaluate the efficacy of SSRI and SNRI antidepressants,so as to provide reference for the individualized and precise treatment,expecting to improve antidepressant effect.